-DOCSTART- -X- O
Previously -X- _ O
, -X- _ O
recombinant -X- _ O
vesicular -X- _ O
stomatitis -X- _ O
virus -X- _ O
( -X- _ O
rVSV -X- _ O
) -X- _ O
pseudotypes -X- _ O
expressing -X- _ O
Ebolavirus -X- _ O
glycoproteins -X- _ O
( -X- _ O
GPs -X- _ O
) -X- _ O
in -X- _ O
place -X- _ O
of -X- _ O
the -X- _ O
VSV -X- _ O
G -X- _ O
protein -X- _ O
demonstrated -X- _ O
protection -X- _ O
of -X- _ O
nonhuman -X- _ B-Patient
primates -X- _ I-Patient
from -X- _ O
lethal -X- _ O
homologous -X- _ O
Ebolavirus -X- _ O
challenge. -X- _ O
Those -X- _ O
pseudotype -X- _ O
vectors -X- _ O
contained -X- _ O
no -X- _ O
additional -X- _ O
attenuating -X- _ O
mutations -X- _ O
in -X- _ O
the -X- _ O
rVSV -X- _ O
genome. -X- _ O
Here -X- _ O
we -X- _ O
describe -X- _ O
rVSV -X- _ B-Intervention
vectors -X- _ I-Intervention
containing -X- _ I-Intervention
a -X- _ I-Intervention
full -X- _ I-Intervention
complement -X- _ I-Intervention
of -X- _ I-Intervention
VSV -X- _ I-Intervention
genes -X- _ I-Intervention
and -X- _ I-Intervention
expressing -X- _ I-Intervention
the -X- _ I-Intervention
Ebola -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
EBOV -X- _ I-Intervention
) -X- _ I-Intervention
GP -X- _ I-Intervention
from -X- _ I-Intervention
an -X- _ I-Intervention
additional -X- _ I-Intervention
transcription -X- _ I-Intervention
unit. -X- _ I-Intervention
These -X- _ O
rVSV -X- _ O
vectors -X- _ O
contain -X- _ O
the -X- _ O
same -X- _ O
combination -X- _ O
of -X- _ O
attenuating -X- _ O
mutations -X- _ O
used -X- _ O
previously -X- _ O
in -X- _ O
the -X- _ O
clinical -X- _ O
development -X- _ O
pathway -X- _ O
of -X- _ O
an -X- _ O
rVSV -X- _ O
/ -X- _ O
human -X- _ O
immunodeficiency -X- _ O
virus -X- _ O
type -X- _ O
1 -X- _ O
vaccine. -X- _ O
One -X- _ O
of -X- _ O
these -X- _ O
rVSV -X- _ O
vectors -X- _ O
( -X- _ O
N4CT1-EBOVGP1 -X- _ B-Intervention
) -X- _ O
, -X- _ O
which -X- _ O
expresses -X- _ O
membrane-anchored -X- _ O
EBOV -X- _ O
GP -X- _ O
from -X- _ O
the -X- _ O
first -X- _ O
position -X- _ O
in -X- _ O
the -X- _ O
genome -X- _ O
( -X- _ O
GP1 -X- _ O
) -X- _ O
, -X- _ O
elicited -X- _ B-Outcome
a -X- _ I-Outcome
balanced -X- _ I-Outcome
cellular -X- _ I-Outcome
and -X- _ I-Outcome
humoral -X- _ I-Outcome
GP-specific -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
in -X- _ I-Outcome
mice. -X- _ I-Outcome
Guinea -X- _ B-Patient
pigs -X- _ I-Patient
immunized -X- _ B-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
single -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
this -X- _ I-Outcome
vector -X- _ I-Outcome
were -X- _ I-Outcome
protected -X- _ I-Outcome
from -X- _ I-Outcome
any -X- _ I-Outcome
signs -X- _ I-Outcome
of -X- _ I-Outcome
disease -X- _ I-Outcome
following -X- _ I-Outcome
lethal -X- _ I-Outcome
EBOV -X- _ I-Outcome
challenge -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
control -X- _ I-Outcome
animals -X- _ I-Outcome
died -X- _ I-Outcome
in -X- _ I-Outcome
7â€“9 -X- _ I-Outcome
days. -X- _ I-Outcome
Subsequently -X- _ O
, -X- _ O
N4CT1-EBOVGP1 -X- _ B-Intervention
demonstrated -X- _ O
complete -X- _ B-Outcome
, -X- _ I-Outcome
single-dose -X- _ I-Outcome
protection -X- _ I-Outcome
of -X- _ I-Outcome
2 -X- _ I-Outcome
macaques -X- _ I-Outcome
following -X- _ I-Outcome
lethal -X- _ I-Outcome
EBOV -X- _ I-Outcome
challenge. -X- _ I-Outcome
A -X- _ I-Outcome
single -X- _ I-Outcome
sham-vaccinated -X- _ I-Outcome
macaque -X- _ I-Outcome
died -X- _ I-Outcome
from -X- _ I-Outcome
disease -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
EBOV -X- _ I-Outcome
infection. -X- _ I-Outcome
These -X- _ O
results -X- _ O
demonstrate -X- _ O
that -X- _ O
highly -X- _ O
attenuated -X- _ O
rVSV -X- _ O
vectors -X- _ O
expressing -X- _ O
EBOV -X- _ O
GP -X- _ O
may -X- _ O
provide -X- _ O
safer -X- _ O
alternatives -X- _ O
to -X- _ O
current -X- _ O
EBOV -X- _ O
vaccines -X- _ O
. -X- _ O

